3M Company (MMM) Balance Sheet

The asset shrinkage appears largely attributable to the Health Care spin-off rather than organic deleveraging, as total liabilities have declined more slowly than assets in recent quarters. Equity has remained trapped in a $3.0B–$4.7B band across all ten periods despite retained earnings accumulating to nearly $40B, a divergence that signals the book capital base is being continuously absorbed rather than rebuilt.

The 2026Q3 debt build coincided with a $1.8B cash recovery from $3.0B, which may indicate deliberate issuance to pre-fund settlement outflows rather than distress-driven borrowing, though the absence of maturity breakdowns limits certainty. When paired with the cash flow finding that operating cash flow trailed cumulative net income by roughly $4.0B over ten quarters, the capacity to organically de-lever appears constrained.

The current ratio improvement appears driven more by current liability management than by a rebuild of liquid assets, since cash did not return to its 2024 highs and granular working-capital detail is unavailable. Given that cumulative dividends and buybacks consumed approximately $13.4B against only $2.9B of free cash flow over the same ten quarters, the erosion of the cash buffer appears externally financed, which may materially reduce the cushion available for the multi-billion-dollar PFAS settlement schedule.

This divergence most plausibly reflects pension mark-to-market charges, unrealized investment writedowns, and cumulative foreign currency translation losses, all of which are plausible given 3M's legacy defined-benefit obligations and global manufacturing footprint. While an accounting drag rather than a cash liability, it means book equity offers almost no creditor cushion — as underscored by the near-zero print of $3.0B in 2026Q2 — and investors should monitor whether further AOCI deterioration could push equity toward zero.